Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Inclusion Criteria: * Adults ≥ 18 to ≤ 60 years of age at the time of signing the informed consent form. * History of migraine (with or without aura) for ≥ 12 months before screening according to the International Headache Society (IHS) Classification ICHD-III (Headache Classification Committee of the International Headache Society, 2013) * Migraine frequency: ≥ 4 migraine days per month on average across the 3 months before screening. * Failed at least 1 medication for prophylactic treatment of migraine due to tolerability or lack of efficacy Exclusion Criteria: * Older than 50 years of age at migraine onset. * History of cluster headache, hemiplegic migraine headache. * Unable to differentiate migraine from other headaches. * Migraine with continuous pain, in which the subject does not experience any pain-free periods (of any duration) during the 1 month before the screening period. * History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.